Island Pharmaceuticals Ltd (ASX:ILA) CEO Dr David Foster tells Proactive the company has been granted human research ethics approval to commence its ISLA-101 Single Ascending Dose study. The aim of the study is to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus. Recruitment and dosing will commence imminently, with the data read out expected in early 2024.
Foster said, “Ethics approval was the final step in being able to commence our Single Ascending Dose study for ISLA-101 and we now look forward to recruiting and dosing our first subject shortly. If all runs smoothly, our aim is to have final data by early 2024 and then rapidly transition to the Phase 2 PEACH study soon thereafter.
“The need for dengue fever preventative and treatment options is more urgent than ever, with the disease now endemic in more than 100 countries, including record cases in Europe and recent major outbreaks in countries such as Peru, Jamaica and Bangladesh.”
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744